Review of Non-Small Cell Lung Cancer and Therapies Available
Posted on: Monday, 27 August 2007, 09:13 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c66718) has announced the addition of "Disease and Therapy Review: Non-Small Cell Lung Cancer" to their offering.
The Non-Small Cell Lung Cancer (NSCLC) Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis and staging, and an overview of treatments by disease stage. General sales information is included for several chemotherapy agents, although not broken out for NSCLC specifically.
Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by a senior market research team. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends.
The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Langes Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.
Key Topics Covered Include:
Overview
Incidence and Prevalence
Diagnosis
Treatment
Market Size
Comments
References/Resources
For more information visit http://www.researchandmarkets.com/reports/c66718
Source: Business Wire
Related Articles
- Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
- Generic Erosion of Market Leading Therapies Will Constrain Growth in the Parkinson's Disease Drug Market Over the Next Decade
- Despite Availability of Numerous Generic Antidepressants, Forest Laboratories' Lexapro Retains Leadership Among First-Line Therapies in the Treatment of Major Depression
- Forest Laboratories' Lexapro and Pfizer's Prozac Lead First-Line Therapy in the Treatment for Major Depression
- Focus on the Alzheimer's and Parkinson's Disease Drugs Market: Drug Classification, Future Therapies and Key Players
- Corgenix Reports New Clinical Data Correlating AtherOx(TM) Technology With Vascular Disease
- Autoimmune Disease Therapeutics Market to Gain From Increased Acceptance of Biologics By Physicians - European Autoimmune Diseases Therapeutics Markets
- Boston Doctors Discover Treatment for Potentially Fatal Autoimmune Skin Disease; Reported in NEJM
- European Commission Approves Keppra(R) for Use As Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients With Juvenile Myoclonic Epilepsy
- Eisai Announces Phase II Data on E7389, a Potential New Therapy for the Treatment of Breast Cancer
 |
 |
User Comments (0)
RSS Feeds